Andrew “Drew” Ehle has experience preparing and prosecuting patents, both domestically and internationally, in the technical areas of pharmaceuticals, chemistry, and biotechnology.
His intellectual property capabilities extend to portfolio management, client consultation, inventorship, freedom to operate, patentability and due diligence analyses, and strategic intellectual property counseling.
Drew’s knowledge covers a wide range of subject matters, including small molecules, antisense oligomers, RNA and DNA analogs, antibody drug conjugates, polymers, fuel additives, organic synthesis and methodology development, fast-flow synthesis, formulations, polymorphs, and prodrugs. During his career, Drew has had the opportunity to prosecute multiple U.S. Food and Drug Administration Orange Book-listed patents.
Before joining the firm, Drew was a research chemist with a strong background in methodology development. Drew earned his doctorate at the University of Delaware, where he worked as a graduate student in the lab of Professor Mary Watson investigating the formation of carbon-carbon bonds using cheap and ubiquitous nickel catalysts to activate carbon-oxygen bonds, and the formation of previously unexplored carbon-carbon bonds using Lewis Acid catalysts to activate vinyl halides. Drew also worked as a postdoctoral fellow in the lab of Tyler McQuade at Florida State University and in the lab of Frank Gupton at the Department of Engineering at Virginia Commonwealth University, where he partnered with The Bill and Melinda Gates Medicine for All Foundation on work involving novel copper catalysts for forming carbon-carbon bonds. During his postdoctoral research, Drew also developed an improved synthesis of potent anti-HIV drugs using a continuous reactor process (flow chemistry) to synthesize hydroxyl propyl adenine, a key component of many anti-HIV drugs.
- B.A. in Chemistry, West Chester University
- Ph.D. in Organic Chemistry, University of Delaware
- J.D., Suffolk University Law School
- Co-speaker, What constitutes an inventor? A review of Federal Circuit case law, 256th ACS National Meeting in Boston, MA, August 19-23, 2018
- Co-Speaker, Formation of Highly Substituted Vinyl Bromides, 247thACS National Meeting, March 2014
- Co-Speaker, Nickel-Catalyzed Heck Cross-Couplings via Activation of Strong C-O Bonds, 43rd Middle Atlantic Regional Meeting of the American Chemical Society, May-June 2012
- Co-Speaker, Nickel-Catalyzed Heck Cross-Couplings via Activation of Strong C-O Bonds, ACS National Meeting, August 2012
- Co-Speaker, DiaryInorbornadiene Derivatives: Synthesis and Initial Photochemical Studies, 236th ACS National Meeting, August 2008
1. Ehle, Andrew R.; Morris, Melissa; Klebon, Bryan; Yap, Glenn; Watson, Mary P. “Stereoselective Synthesis of Trisubstituted Vinyl Bromides via Addition of Alkynes to Oxocarbenium Ions” Synlett 2015, 26(19), 2702-2706
2. Ehle, Andrew R.; Zhou, Qi; Watson, Mary P. “Nickel(0)-Catalyzed Heck Cross-Coupling via Activation of Aryl C-OPiv Bonds” Organic Letters 2012, 14(5), 1202-1205
3. Jennifer W. Eddy, Evan A. Davey, Richard D. Malsom, Andrew R. Ehle, Scott Kassel and Felix E. Goodson. “Palladium Complexes with Aqueous Partitioning Dibenzylideneacetone Ligands. A New Strategy for Catalyst Design in Suzuki Polycondensation Reactions” Macromolecules 2009, 42 (22), 8611–8614
4. Minyoung Jo, Daniel Rivalti, Andrew R. Ehle, Alina Dragulescu-Andrasi, Manuel Hartweg, Michael Shatruk, Tyler McQuade. “Understanding Six-Membered NHC-Copper(I) Allylic Borylation Selectivity by Comparison with other Catalystsand Different Substrates.” Synlett 2018, 29(20), 2673-2678
5. Kyle J. Spivack, Jesse V. Walker, Maria J. Sanford, Benjamin R. Rupert, Andrew R. Ehle, James M. Tocyloski, Aaron N. Jahn, Lyndsey M. Shaak, Obiamaka Obianyo, Karyn M. Usher, and Felix E. Goodson. “Substituted Diarylnorbornadienes and Quadricyclanes: Synthesis, Photochemical Properties, and Effect of Substituent on the Kinetic Stability of Quadricyclanes .” The Journal of organic Chemistry 2017, 82(3), 1301-1315. Tech Transfer Documents
6. “Process Optimization: Tenofovir and Prodrug Adducts” Bill and Melinda Gates: Medicines for All Initiative. 2016
- Boston Patent Law Association